📊 Get daily AI-graded market briefings
Morning + evening · AI impact + sector exposure · Free
LAST 30 DAYS
0 articles
AVG GRADE
HIGH
score: 0.75
SENTIMENT
NEUTRAL
TOTAL VIEWS
117
PSNL Latest News & AI Sentiment Analysis
0 articles · Grade: HIGH · Real-time AI-graded coverage
RECENT COVERAGE · 7 ARTICLES
Personalis: Tempus Bought The Best Part Of The Story (NASDAQ:PSNL)
Personalis (PSNL) has reached a meaningful inflection point driven by clinical adoption and Medicare reimbursement expansion, validating...
Tempus AI Acquires Personalis: Why Both Stocks Are A Buy Now (NASDAQ:TEM)
Tempus AI's acquisition of Personalis represents a significant consolidation play in the precision oncology diagnostics space. The deal...
Personalis, Inc. (PSNL) M&A Call Transcript
Personalis (PSNL) announced a material M&A transaction, representing a significant capital event for the precision oncology and genomic...
Personalis, Inc. (PSNL) Tempus AI, Inc. - M&A Call - Slideshow (NASDAQ:PSNL) 2026-07-20
Personalis (PSNL) and Tempus AI (TEM) announced a merger combination, representing a significant consolidation in the genomic sequencing...
Personalis Stock Falls 10% After Agreeing To Acquisition Deal By Tempus AI
PSNL experienced a sharp 10% single-session decline following announcement of its acquisition by Tempus AI, a development that signals...
Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform
Tempus AI (TEM) announced a definitive acquisition of Personalis (PSNL), a genomics-focused precision oncology company. This deal...
Personalis is said to have attracted takeover interest from Merck
Personalis has reportedly attracted takeover interest from pharmaceutical giant Merck, representing a potential consolidation move...
RELATED TICKERS
E
ESEN Analytics
AI-powered equity research platform covering 5,000+ US equities. Our proprietary AI grading system (A+ to D scale) analyzes fundamentals, technicals, and news sentiment daily. Coverage data updated every 24 hours.
Learn about our methodology →
ⓘ AI-graded news coverage · Not investment advice